Loading…

Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial

BACKGROUND:Outcome trials in patients with type 2 diabetes mellitus have demonstrated reduced hospitalizations for heart failure (HF) with sodium-glucose co-transporter-2 inhibitors. However, few of these patients had HF, and those that did were not well-characterized. Thus, the effects of sodium-gl...

Full description

Saved in:
Bibliographic Details
Published in:Circulation (New York, N.Y.) N.Y.), 2019-10, Vol.140 (18), p.1463-1476
Main Authors: Nassif, Michael E, Windsor, Sheryl L, Tang, Fengming, Khariton, Yevgeniy, Husain, Mansoor, Inzucchi, Silvio E, Mc-Guire, Darren K, Pitt, Bertram, Scirica, Benjamin M, Austin, Bethany, Drazner, Mark H, Fong, Michael W, Givertz, Michael M, Gordon, Robert A, Jermyn, Rita, Katz, Stuart D, Lamba, Sumant, Lanfear, David E, LaRue, Shane J, Lindenfeld, JoAnn, Malone, Michael, Margulies, Kenneth, Mentz, Robert J, Mutharasan, R Kannan, Pursley, Michael, Umpierrez, Guillermo, Kosiborod, Mikhail, Malik, Ali O, Wenger, Nannette, Ogunniyi, Modele, Vellanki, Priyathama, Murphy, Brenda, Newman, Jonathan, Hartupee, Justin, Gupta, Charu, Goldsmith, Marcela, Baweja, Paramdeep, Montero, Manuel, Gottlieb, Stephen S, Costanzo, Maria Rosa, Hoang, Thanh, Warnock, Alicia, Allen, Larry, Tang, Wilson, Chen, Horng H, Cox, John M
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c2925-9d7a4a5b3ad4bd098b92daa7810087f664e3c9c0ea0ab5ce542ae2fb6009f3a73
cites cdi_FETCH-LOGICAL-c2925-9d7a4a5b3ad4bd098b92daa7810087f664e3c9c0ea0ab5ce542ae2fb6009f3a73
container_end_page 1476
container_issue 18
container_start_page 1463
container_title Circulation (New York, N.Y.)
container_volume 140
creator Nassif, Michael E
Windsor, Sheryl L
Tang, Fengming
Khariton, Yevgeniy
Husain, Mansoor
Inzucchi, Silvio E
Mc-Guire, Darren K
Pitt, Bertram
Scirica, Benjamin M
Austin, Bethany
Drazner, Mark H
Fong, Michael W
Givertz, Michael M
Gordon, Robert A
Jermyn, Rita
Katz, Stuart D
Lamba, Sumant
Lanfear, David E
LaRue, Shane J
Lindenfeld, JoAnn
Malone, Michael
Margulies, Kenneth
Mentz, Robert J
Mutharasan, R Kannan
Pursley, Michael
Umpierrez, Guillermo
Kosiborod, Mikhail
Malik, Ali O
Wenger, Nannette
Ogunniyi, Modele
Vellanki, Priyathama
Murphy, Brenda
Newman, Jonathan
Hartupee, Justin
Gupta, Charu
Goldsmith, Marcela
Baweja, Paramdeep
Montero, Manuel
Gottlieb, Stephen S
Costanzo, Maria Rosa
Hoang, Thanh
Warnock, Alicia
Allen, Larry
Tang, Wilson
Chen, Horng H
Cox, John M
description BACKGROUND:Outcome trials in patients with type 2 diabetes mellitus have demonstrated reduced hospitalizations for heart failure (HF) with sodium-glucose co-transporter-2 inhibitors. However, few of these patients had HF, and those that did were not well-characterized. Thus, the effects of sodium-glucose co-transporter-2 inhibitors in patients with established HF with reduced ejection fraction, including those with and without type 2 diabetes mellitus, remain unknown. METHODS:DEFINE-HF (Dapagliflozin Effects on Biomarkers, Symptoms and Functional Status in Patients with HF with Reduced Ejection Fraction) was an investigator-initiated, multi-center, randomized controlled trial of HF patients with left ventricular ejection fraction ≤40%, New York Heart Association (NYHA) class II-III, estimated glomerular filtration rate ≥30 mL/min/1.73m, and elevated natriuretic peptides. In total, 263 patients were randomized to dapagliflozin 10 mg daily or placebo for 12 weeks. Dual primary outcomes were (1) mean NT-proBNP (N-terminal pro b-type natriuretic peptide) and (2) proportion of patients with ≥5-point increase in HF disease-specific health status on the Kansas City Cardiomyopathy Questionnaire overall summary score, or a ≥20% decrease in NT-proBNP. RESULTS:Patient characteristics reflected stable, chronic HF with reduced ejection fraction with high use of optimal medical therapy. There was no significant difference in average 6- and 12-week adjusted NT-proBNP with dapagliflozin versus placebo (1133 pg/dL (95% CI 1036–1238) vs 1191 pg/dL (95% CI 1089–1304), P=0.43). For the second dual-primary outcome of a meaningful improvement in Kansas City Cardiomyopathy Questionnaire overall summary score or NT-proBNP, 61.5% of dapagliflozin-treated patients met this end point versus 50.4% with placebo (adjusted OR 1.8, 95% CI 1.03-3.06, nominal P=0.039). This was attributable to both higher proportions of patients with ≥5-point improvement in Kansas City Cardiomyopathy Questionnaire overall summary score (42.9 vs 32.5%, adjusted OR 1.73, 95% CI 0.98–3.05), and ≥20% reduction in NT-proBNP (44.0 vs 29.4%, adjusted OR 1.9, 95% CI 1.1–3.3) by 12 weeks. Results were consistent among patients with or without type 2 diabetes mellitus, and other prespecified subgroups (all P values for interaction=NS). CONCLUSIONS:In patients with heart failure and reduced ejection fraction, use of dapagliflozin over 12 weeks did not affect mean NT-proBNP but increased the proportion of patients exp
doi_str_mv 10.1161/CIRCULATIONAHA.119.042929
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2290967110</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2290967110</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2925-9d7a4a5b3ad4bd098b92daa7810087f664e3c9c0ea0ab5ce542ae2fb6009f3a73</originalsourceid><addsrcrecordid>eNpVkUtv1DAUhS1E1Q6lfwGZHQtS_MhjzG46TZiRRi1qp2IZ3SQ3jFsnGWxHVfkj_F08TYvEytdH5_PjHEI-cnbOecq_LNc3y7vNYru-vlqsFkFT5ywWSqg3ZMYTEUdxItVbMmOMqSiTQpyQd87dh20qs-SYnMiDK1bzGflzCXv4aXRrht-6p3nbYu0dHXp6oYcO7ANa95nePnV7P3Rhgr6hxdjXXg89GHrrwY-OBvI7eI19QH9ov6MrBOtpAdqMFifpBpuxxobm9_hM08LC8_CVbndIL_NifZVHq4JurQbznhy1YByevayn5K7It8tVtLn-tl4uNlEd_ptEqskghqSS0MRVw9S8UqIByOacsXnWpmmMslY1Q2BQJTUmsQAUbZWGZFoJmTwln6Zz93b4NaLzZaddjcZAj8PoSiEUU2nGOQtWNVlrOzhnsS33VoeInkrOykMv5f-9BE2VUy-B_fByzVh12PwjX4sIhngyPA7Gh8wfzPiIttwhGL8rQ3NMMp5FgnHFWXhTdJAS-RcEeZtm</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2290967110</pqid></control><display><type>article</type><title>Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial</title><source>EZB Electronic Journals Library</source><creator>Nassif, Michael E ; Windsor, Sheryl L ; Tang, Fengming ; Khariton, Yevgeniy ; Husain, Mansoor ; Inzucchi, Silvio E ; Mc-Guire, Darren K ; Pitt, Bertram ; Scirica, Benjamin M ; Austin, Bethany ; Drazner, Mark H ; Fong, Michael W ; Givertz, Michael M ; Gordon, Robert A ; Jermyn, Rita ; Katz, Stuart D ; Lamba, Sumant ; Lanfear, David E ; LaRue, Shane J ; Lindenfeld, JoAnn ; Malone, Michael ; Margulies, Kenneth ; Mentz, Robert J ; Mutharasan, R Kannan ; Pursley, Michael ; Umpierrez, Guillermo ; Kosiborod, Mikhail ; Malik, Ali O ; Wenger, Nannette ; Ogunniyi, Modele ; Vellanki, Priyathama ; Murphy, Brenda ; Newman, Jonathan ; Hartupee, Justin ; Gupta, Charu ; Goldsmith, Marcela ; Baweja, Paramdeep ; Montero, Manuel ; Gottlieb, Stephen S ; Costanzo, Maria Rosa ; Hoang, Thanh ; Warnock, Alicia ; Allen, Larry ; Tang, Wilson ; Chen, Horng H ; Cox, John M</creator><creatorcontrib>Nassif, Michael E ; Windsor, Sheryl L ; Tang, Fengming ; Khariton, Yevgeniy ; Husain, Mansoor ; Inzucchi, Silvio E ; Mc-Guire, Darren K ; Pitt, Bertram ; Scirica, Benjamin M ; Austin, Bethany ; Drazner, Mark H ; Fong, Michael W ; Givertz, Michael M ; Gordon, Robert A ; Jermyn, Rita ; Katz, Stuart D ; Lamba, Sumant ; Lanfear, David E ; LaRue, Shane J ; Lindenfeld, JoAnn ; Malone, Michael ; Margulies, Kenneth ; Mentz, Robert J ; Mutharasan, R Kannan ; Pursley, Michael ; Umpierrez, Guillermo ; Kosiborod, Mikhail ; Malik, Ali O ; Wenger, Nannette ; Ogunniyi, Modele ; Vellanki, Priyathama ; Murphy, Brenda ; Newman, Jonathan ; Hartupee, Justin ; Gupta, Charu ; Goldsmith, Marcela ; Baweja, Paramdeep ; Montero, Manuel ; Gottlieb, Stephen S ; Costanzo, Maria Rosa ; Hoang, Thanh ; Warnock, Alicia ; Allen, Larry ; Tang, Wilson ; Chen, Horng H ; Cox, John M ; On behalf of the DEFINE-HF Investigators</creatorcontrib><description>BACKGROUND:Outcome trials in patients with type 2 diabetes mellitus have demonstrated reduced hospitalizations for heart failure (HF) with sodium-glucose co-transporter-2 inhibitors. However, few of these patients had HF, and those that did were not well-characterized. Thus, the effects of sodium-glucose co-transporter-2 inhibitors in patients with established HF with reduced ejection fraction, including those with and without type 2 diabetes mellitus, remain unknown. METHODS:DEFINE-HF (Dapagliflozin Effects on Biomarkers, Symptoms and Functional Status in Patients with HF with Reduced Ejection Fraction) was an investigator-initiated, multi-center, randomized controlled trial of HF patients with left ventricular ejection fraction ≤40%, New York Heart Association (NYHA) class II-III, estimated glomerular filtration rate ≥30 mL/min/1.73m, and elevated natriuretic peptides. In total, 263 patients were randomized to dapagliflozin 10 mg daily or placebo for 12 weeks. Dual primary outcomes were (1) mean NT-proBNP (N-terminal pro b-type natriuretic peptide) and (2) proportion of patients with ≥5-point increase in HF disease-specific health status on the Kansas City Cardiomyopathy Questionnaire overall summary score, or a ≥20% decrease in NT-proBNP. RESULTS:Patient characteristics reflected stable, chronic HF with reduced ejection fraction with high use of optimal medical therapy. There was no significant difference in average 6- and 12-week adjusted NT-proBNP with dapagliflozin versus placebo (1133 pg/dL (95% CI 1036–1238) vs 1191 pg/dL (95% CI 1089–1304), P=0.43). For the second dual-primary outcome of a meaningful improvement in Kansas City Cardiomyopathy Questionnaire overall summary score or NT-proBNP, 61.5% of dapagliflozin-treated patients met this end point versus 50.4% with placebo (adjusted OR 1.8, 95% CI 1.03-3.06, nominal P=0.039). This was attributable to both higher proportions of patients with ≥5-point improvement in Kansas City Cardiomyopathy Questionnaire overall summary score (42.9 vs 32.5%, adjusted OR 1.73, 95% CI 0.98–3.05), and ≥20% reduction in NT-proBNP (44.0 vs 29.4%, adjusted OR 1.9, 95% CI 1.1–3.3) by 12 weeks. Results were consistent among patients with or without type 2 diabetes mellitus, and other prespecified subgroups (all P values for interaction=NS). CONCLUSIONS:In patients with heart failure and reduced ejection fraction, use of dapagliflozin over 12 weeks did not affect mean NT-proBNP but increased the proportion of patients experiencing clinically meaningful improvements in HF-related health status or natriuretic peptides. Benefits of dapagliflozin on clinically meaningful HF measures appear to extend to patients without type 2 diabetes mellitus. CLINICAL TRIAL REGISTRATION:URLhttps://www.clinicaltrials.gov. Unique identifierNCT 02653482.</description><identifier>ISSN: 0009-7322</identifier><identifier>EISSN: 1524-4539</identifier><identifier>DOI: 10.1161/CIRCULATIONAHA.119.042929</identifier><identifier>PMID: 31524498</identifier><language>eng</language><publisher>United States: by the American College of Cardiology Foundation and the American Heart Association, Inc</publisher><subject>Aged ; Benzhydryl Compounds - pharmacology ; Biomarkers - analysis ; Diabetes Mellitus, Type 2 - complications ; Diabetes Mellitus, Type 2 - drug therapy ; Female ; Glucosides - pharmacology ; Heart Failure - drug therapy ; Heart Failure - physiopathology ; Humans ; Male ; Middle Aged ; Stroke Volume - drug effects ; Ventricular Dysfunction, Left - drug therapy ; Ventricular Function, Left - drug effects</subject><ispartof>Circulation (New York, N.Y.), 2019-10, Vol.140 (18), p.1463-1476</ispartof><rights>2019 by the American College of Cardiology Foundation and the American Heart Association, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2925-9d7a4a5b3ad4bd098b92daa7810087f664e3c9c0ea0ab5ce542ae2fb6009f3a73</citedby><cites>FETCH-LOGICAL-c2925-9d7a4a5b3ad4bd098b92daa7810087f664e3c9c0ea0ab5ce542ae2fb6009f3a73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31524498$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nassif, Michael E</creatorcontrib><creatorcontrib>Windsor, Sheryl L</creatorcontrib><creatorcontrib>Tang, Fengming</creatorcontrib><creatorcontrib>Khariton, Yevgeniy</creatorcontrib><creatorcontrib>Husain, Mansoor</creatorcontrib><creatorcontrib>Inzucchi, Silvio E</creatorcontrib><creatorcontrib>Mc-Guire, Darren K</creatorcontrib><creatorcontrib>Pitt, Bertram</creatorcontrib><creatorcontrib>Scirica, Benjamin M</creatorcontrib><creatorcontrib>Austin, Bethany</creatorcontrib><creatorcontrib>Drazner, Mark H</creatorcontrib><creatorcontrib>Fong, Michael W</creatorcontrib><creatorcontrib>Givertz, Michael M</creatorcontrib><creatorcontrib>Gordon, Robert A</creatorcontrib><creatorcontrib>Jermyn, Rita</creatorcontrib><creatorcontrib>Katz, Stuart D</creatorcontrib><creatorcontrib>Lamba, Sumant</creatorcontrib><creatorcontrib>Lanfear, David E</creatorcontrib><creatorcontrib>LaRue, Shane J</creatorcontrib><creatorcontrib>Lindenfeld, JoAnn</creatorcontrib><creatorcontrib>Malone, Michael</creatorcontrib><creatorcontrib>Margulies, Kenneth</creatorcontrib><creatorcontrib>Mentz, Robert J</creatorcontrib><creatorcontrib>Mutharasan, R Kannan</creatorcontrib><creatorcontrib>Pursley, Michael</creatorcontrib><creatorcontrib>Umpierrez, Guillermo</creatorcontrib><creatorcontrib>Kosiborod, Mikhail</creatorcontrib><creatorcontrib>Malik, Ali O</creatorcontrib><creatorcontrib>Wenger, Nannette</creatorcontrib><creatorcontrib>Ogunniyi, Modele</creatorcontrib><creatorcontrib>Vellanki, Priyathama</creatorcontrib><creatorcontrib>Murphy, Brenda</creatorcontrib><creatorcontrib>Newman, Jonathan</creatorcontrib><creatorcontrib>Hartupee, Justin</creatorcontrib><creatorcontrib>Gupta, Charu</creatorcontrib><creatorcontrib>Goldsmith, Marcela</creatorcontrib><creatorcontrib>Baweja, Paramdeep</creatorcontrib><creatorcontrib>Montero, Manuel</creatorcontrib><creatorcontrib>Gottlieb, Stephen S</creatorcontrib><creatorcontrib>Costanzo, Maria Rosa</creatorcontrib><creatorcontrib>Hoang, Thanh</creatorcontrib><creatorcontrib>Warnock, Alicia</creatorcontrib><creatorcontrib>Allen, Larry</creatorcontrib><creatorcontrib>Tang, Wilson</creatorcontrib><creatorcontrib>Chen, Horng H</creatorcontrib><creatorcontrib>Cox, John M</creatorcontrib><creatorcontrib>On behalf of the DEFINE-HF Investigators</creatorcontrib><title>Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial</title><title>Circulation (New York, N.Y.)</title><addtitle>Circulation</addtitle><description>BACKGROUND:Outcome trials in patients with type 2 diabetes mellitus have demonstrated reduced hospitalizations for heart failure (HF) with sodium-glucose co-transporter-2 inhibitors. However, few of these patients had HF, and those that did were not well-characterized. Thus, the effects of sodium-glucose co-transporter-2 inhibitors in patients with established HF with reduced ejection fraction, including those with and without type 2 diabetes mellitus, remain unknown. METHODS:DEFINE-HF (Dapagliflozin Effects on Biomarkers, Symptoms and Functional Status in Patients with HF with Reduced Ejection Fraction) was an investigator-initiated, multi-center, randomized controlled trial of HF patients with left ventricular ejection fraction ≤40%, New York Heart Association (NYHA) class II-III, estimated glomerular filtration rate ≥30 mL/min/1.73m, and elevated natriuretic peptides. In total, 263 patients were randomized to dapagliflozin 10 mg daily or placebo for 12 weeks. Dual primary outcomes were (1) mean NT-proBNP (N-terminal pro b-type natriuretic peptide) and (2) proportion of patients with ≥5-point increase in HF disease-specific health status on the Kansas City Cardiomyopathy Questionnaire overall summary score, or a ≥20% decrease in NT-proBNP. RESULTS:Patient characteristics reflected stable, chronic HF with reduced ejection fraction with high use of optimal medical therapy. There was no significant difference in average 6- and 12-week adjusted NT-proBNP with dapagliflozin versus placebo (1133 pg/dL (95% CI 1036–1238) vs 1191 pg/dL (95% CI 1089–1304), P=0.43). For the second dual-primary outcome of a meaningful improvement in Kansas City Cardiomyopathy Questionnaire overall summary score or NT-proBNP, 61.5% of dapagliflozin-treated patients met this end point versus 50.4% with placebo (adjusted OR 1.8, 95% CI 1.03-3.06, nominal P=0.039). This was attributable to both higher proportions of patients with ≥5-point improvement in Kansas City Cardiomyopathy Questionnaire overall summary score (42.9 vs 32.5%, adjusted OR 1.73, 95% CI 0.98–3.05), and ≥20% reduction in NT-proBNP (44.0 vs 29.4%, adjusted OR 1.9, 95% CI 1.1–3.3) by 12 weeks. Results were consistent among patients with or without type 2 diabetes mellitus, and other prespecified subgroups (all P values for interaction=NS). CONCLUSIONS:In patients with heart failure and reduced ejection fraction, use of dapagliflozin over 12 weeks did not affect mean NT-proBNP but increased the proportion of patients experiencing clinically meaningful improvements in HF-related health status or natriuretic peptides. Benefits of dapagliflozin on clinically meaningful HF measures appear to extend to patients without type 2 diabetes mellitus. CLINICAL TRIAL REGISTRATION:URLhttps://www.clinicaltrials.gov. Unique identifierNCT 02653482.</description><subject>Aged</subject><subject>Benzhydryl Compounds - pharmacology</subject><subject>Biomarkers - analysis</subject><subject>Diabetes Mellitus, Type 2 - complications</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Female</subject><subject>Glucosides - pharmacology</subject><subject>Heart Failure - drug therapy</subject><subject>Heart Failure - physiopathology</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Stroke Volume - drug effects</subject><subject>Ventricular Dysfunction, Left - drug therapy</subject><subject>Ventricular Function, Left - drug effects</subject><issn>0009-7322</issn><issn>1524-4539</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNpVkUtv1DAUhS1E1Q6lfwGZHQtS_MhjzG46TZiRRi1qp2IZ3SQ3jFsnGWxHVfkj_F08TYvEytdH5_PjHEI-cnbOecq_LNc3y7vNYru-vlqsFkFT5ywWSqg3ZMYTEUdxItVbMmOMqSiTQpyQd87dh20qs-SYnMiDK1bzGflzCXv4aXRrht-6p3nbYu0dHXp6oYcO7ANa95nePnV7P3Rhgr6hxdjXXg89GHrrwY-OBvI7eI19QH9ov6MrBOtpAdqMFifpBpuxxobm9_hM08LC8_CVbndIL_NifZVHq4JurQbznhy1YByevayn5K7It8tVtLn-tl4uNlEd_ptEqskghqSS0MRVw9S8UqIByOacsXnWpmmMslY1Q2BQJTUmsQAUbZWGZFoJmTwln6Zz93b4NaLzZaddjcZAj8PoSiEUU2nGOQtWNVlrOzhnsS33VoeInkrOykMv5f-9BE2VUy-B_fByzVh12PwjX4sIhngyPA7Gh8wfzPiIttwhGL8rQ3NMMp5FgnHFWXhTdJAS-RcEeZtm</recordid><startdate>20191029</startdate><enddate>20191029</enddate><creator>Nassif, Michael E</creator><creator>Windsor, Sheryl L</creator><creator>Tang, Fengming</creator><creator>Khariton, Yevgeniy</creator><creator>Husain, Mansoor</creator><creator>Inzucchi, Silvio E</creator><creator>Mc-Guire, Darren K</creator><creator>Pitt, Bertram</creator><creator>Scirica, Benjamin M</creator><creator>Austin, Bethany</creator><creator>Drazner, Mark H</creator><creator>Fong, Michael W</creator><creator>Givertz, Michael M</creator><creator>Gordon, Robert A</creator><creator>Jermyn, Rita</creator><creator>Katz, Stuart D</creator><creator>Lamba, Sumant</creator><creator>Lanfear, David E</creator><creator>LaRue, Shane J</creator><creator>Lindenfeld, JoAnn</creator><creator>Malone, Michael</creator><creator>Margulies, Kenneth</creator><creator>Mentz, Robert J</creator><creator>Mutharasan, R Kannan</creator><creator>Pursley, Michael</creator><creator>Umpierrez, Guillermo</creator><creator>Kosiborod, Mikhail</creator><creator>Malik, Ali O</creator><creator>Wenger, Nannette</creator><creator>Ogunniyi, Modele</creator><creator>Vellanki, Priyathama</creator><creator>Murphy, Brenda</creator><creator>Newman, Jonathan</creator><creator>Hartupee, Justin</creator><creator>Gupta, Charu</creator><creator>Goldsmith, Marcela</creator><creator>Baweja, Paramdeep</creator><creator>Montero, Manuel</creator><creator>Gottlieb, Stephen S</creator><creator>Costanzo, Maria Rosa</creator><creator>Hoang, Thanh</creator><creator>Warnock, Alicia</creator><creator>Allen, Larry</creator><creator>Tang, Wilson</creator><creator>Chen, Horng H</creator><creator>Cox, John M</creator><general>by the American College of Cardiology Foundation and the American Heart Association, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20191029</creationdate><title>Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial</title><author>Nassif, Michael E ; Windsor, Sheryl L ; Tang, Fengming ; Khariton, Yevgeniy ; Husain, Mansoor ; Inzucchi, Silvio E ; Mc-Guire, Darren K ; Pitt, Bertram ; Scirica, Benjamin M ; Austin, Bethany ; Drazner, Mark H ; Fong, Michael W ; Givertz, Michael M ; Gordon, Robert A ; Jermyn, Rita ; Katz, Stuart D ; Lamba, Sumant ; Lanfear, David E ; LaRue, Shane J ; Lindenfeld, JoAnn ; Malone, Michael ; Margulies, Kenneth ; Mentz, Robert J ; Mutharasan, R Kannan ; Pursley, Michael ; Umpierrez, Guillermo ; Kosiborod, Mikhail ; Malik, Ali O ; Wenger, Nannette ; Ogunniyi, Modele ; Vellanki, Priyathama ; Murphy, Brenda ; Newman, Jonathan ; Hartupee, Justin ; Gupta, Charu ; Goldsmith, Marcela ; Baweja, Paramdeep ; Montero, Manuel ; Gottlieb, Stephen S ; Costanzo, Maria Rosa ; Hoang, Thanh ; Warnock, Alicia ; Allen, Larry ; Tang, Wilson ; Chen, Horng H ; Cox, John M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2925-9d7a4a5b3ad4bd098b92daa7810087f664e3c9c0ea0ab5ce542ae2fb6009f3a73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Aged</topic><topic>Benzhydryl Compounds - pharmacology</topic><topic>Biomarkers - analysis</topic><topic>Diabetes Mellitus, Type 2 - complications</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Female</topic><topic>Glucosides - pharmacology</topic><topic>Heart Failure - drug therapy</topic><topic>Heart Failure - physiopathology</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Stroke Volume - drug effects</topic><topic>Ventricular Dysfunction, Left - drug therapy</topic><topic>Ventricular Function, Left - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nassif, Michael E</creatorcontrib><creatorcontrib>Windsor, Sheryl L</creatorcontrib><creatorcontrib>Tang, Fengming</creatorcontrib><creatorcontrib>Khariton, Yevgeniy</creatorcontrib><creatorcontrib>Husain, Mansoor</creatorcontrib><creatorcontrib>Inzucchi, Silvio E</creatorcontrib><creatorcontrib>Mc-Guire, Darren K</creatorcontrib><creatorcontrib>Pitt, Bertram</creatorcontrib><creatorcontrib>Scirica, Benjamin M</creatorcontrib><creatorcontrib>Austin, Bethany</creatorcontrib><creatorcontrib>Drazner, Mark H</creatorcontrib><creatorcontrib>Fong, Michael W</creatorcontrib><creatorcontrib>Givertz, Michael M</creatorcontrib><creatorcontrib>Gordon, Robert A</creatorcontrib><creatorcontrib>Jermyn, Rita</creatorcontrib><creatorcontrib>Katz, Stuart D</creatorcontrib><creatorcontrib>Lamba, Sumant</creatorcontrib><creatorcontrib>Lanfear, David E</creatorcontrib><creatorcontrib>LaRue, Shane J</creatorcontrib><creatorcontrib>Lindenfeld, JoAnn</creatorcontrib><creatorcontrib>Malone, Michael</creatorcontrib><creatorcontrib>Margulies, Kenneth</creatorcontrib><creatorcontrib>Mentz, Robert J</creatorcontrib><creatorcontrib>Mutharasan, R Kannan</creatorcontrib><creatorcontrib>Pursley, Michael</creatorcontrib><creatorcontrib>Umpierrez, Guillermo</creatorcontrib><creatorcontrib>Kosiborod, Mikhail</creatorcontrib><creatorcontrib>Malik, Ali O</creatorcontrib><creatorcontrib>Wenger, Nannette</creatorcontrib><creatorcontrib>Ogunniyi, Modele</creatorcontrib><creatorcontrib>Vellanki, Priyathama</creatorcontrib><creatorcontrib>Murphy, Brenda</creatorcontrib><creatorcontrib>Newman, Jonathan</creatorcontrib><creatorcontrib>Hartupee, Justin</creatorcontrib><creatorcontrib>Gupta, Charu</creatorcontrib><creatorcontrib>Goldsmith, Marcela</creatorcontrib><creatorcontrib>Baweja, Paramdeep</creatorcontrib><creatorcontrib>Montero, Manuel</creatorcontrib><creatorcontrib>Gottlieb, Stephen S</creatorcontrib><creatorcontrib>Costanzo, Maria Rosa</creatorcontrib><creatorcontrib>Hoang, Thanh</creatorcontrib><creatorcontrib>Warnock, Alicia</creatorcontrib><creatorcontrib>Allen, Larry</creatorcontrib><creatorcontrib>Tang, Wilson</creatorcontrib><creatorcontrib>Chen, Horng H</creatorcontrib><creatorcontrib>Cox, John M</creatorcontrib><creatorcontrib>On behalf of the DEFINE-HF Investigators</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Circulation (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nassif, Michael E</au><au>Windsor, Sheryl L</au><au>Tang, Fengming</au><au>Khariton, Yevgeniy</au><au>Husain, Mansoor</au><au>Inzucchi, Silvio E</au><au>Mc-Guire, Darren K</au><au>Pitt, Bertram</au><au>Scirica, Benjamin M</au><au>Austin, Bethany</au><au>Drazner, Mark H</au><au>Fong, Michael W</au><au>Givertz, Michael M</au><au>Gordon, Robert A</au><au>Jermyn, Rita</au><au>Katz, Stuart D</au><au>Lamba, Sumant</au><au>Lanfear, David E</au><au>LaRue, Shane J</au><au>Lindenfeld, JoAnn</au><au>Malone, Michael</au><au>Margulies, Kenneth</au><au>Mentz, Robert J</au><au>Mutharasan, R Kannan</au><au>Pursley, Michael</au><au>Umpierrez, Guillermo</au><au>Kosiborod, Mikhail</au><au>Malik, Ali O</au><au>Wenger, Nannette</au><au>Ogunniyi, Modele</au><au>Vellanki, Priyathama</au><au>Murphy, Brenda</au><au>Newman, Jonathan</au><au>Hartupee, Justin</au><au>Gupta, Charu</au><au>Goldsmith, Marcela</au><au>Baweja, Paramdeep</au><au>Montero, Manuel</au><au>Gottlieb, Stephen S</au><au>Costanzo, Maria Rosa</au><au>Hoang, Thanh</au><au>Warnock, Alicia</au><au>Allen, Larry</au><au>Tang, Wilson</au><au>Chen, Horng H</au><au>Cox, John M</au><aucorp>On behalf of the DEFINE-HF Investigators</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial</atitle><jtitle>Circulation (New York, N.Y.)</jtitle><addtitle>Circulation</addtitle><date>2019-10-29</date><risdate>2019</risdate><volume>140</volume><issue>18</issue><spage>1463</spage><epage>1476</epage><pages>1463-1476</pages><issn>0009-7322</issn><eissn>1524-4539</eissn><abstract>BACKGROUND:Outcome trials in patients with type 2 diabetes mellitus have demonstrated reduced hospitalizations for heart failure (HF) with sodium-glucose co-transporter-2 inhibitors. However, few of these patients had HF, and those that did were not well-characterized. Thus, the effects of sodium-glucose co-transporter-2 inhibitors in patients with established HF with reduced ejection fraction, including those with and without type 2 diabetes mellitus, remain unknown. METHODS:DEFINE-HF (Dapagliflozin Effects on Biomarkers, Symptoms and Functional Status in Patients with HF with Reduced Ejection Fraction) was an investigator-initiated, multi-center, randomized controlled trial of HF patients with left ventricular ejection fraction ≤40%, New York Heart Association (NYHA) class II-III, estimated glomerular filtration rate ≥30 mL/min/1.73m, and elevated natriuretic peptides. In total, 263 patients were randomized to dapagliflozin 10 mg daily or placebo for 12 weeks. Dual primary outcomes were (1) mean NT-proBNP (N-terminal pro b-type natriuretic peptide) and (2) proportion of patients with ≥5-point increase in HF disease-specific health status on the Kansas City Cardiomyopathy Questionnaire overall summary score, or a ≥20% decrease in NT-proBNP. RESULTS:Patient characteristics reflected stable, chronic HF with reduced ejection fraction with high use of optimal medical therapy. There was no significant difference in average 6- and 12-week adjusted NT-proBNP with dapagliflozin versus placebo (1133 pg/dL (95% CI 1036–1238) vs 1191 pg/dL (95% CI 1089–1304), P=0.43). For the second dual-primary outcome of a meaningful improvement in Kansas City Cardiomyopathy Questionnaire overall summary score or NT-proBNP, 61.5% of dapagliflozin-treated patients met this end point versus 50.4% with placebo (adjusted OR 1.8, 95% CI 1.03-3.06, nominal P=0.039). This was attributable to both higher proportions of patients with ≥5-point improvement in Kansas City Cardiomyopathy Questionnaire overall summary score (42.9 vs 32.5%, adjusted OR 1.73, 95% CI 0.98–3.05), and ≥20% reduction in NT-proBNP (44.0 vs 29.4%, adjusted OR 1.9, 95% CI 1.1–3.3) by 12 weeks. Results were consistent among patients with or without type 2 diabetes mellitus, and other prespecified subgroups (all P values for interaction=NS). CONCLUSIONS:In patients with heart failure and reduced ejection fraction, use of dapagliflozin over 12 weeks did not affect mean NT-proBNP but increased the proportion of patients experiencing clinically meaningful improvements in HF-related health status or natriuretic peptides. Benefits of dapagliflozin on clinically meaningful HF measures appear to extend to patients without type 2 diabetes mellitus. CLINICAL TRIAL REGISTRATION:URLhttps://www.clinicaltrials.gov. Unique identifierNCT 02653482.</abstract><cop>United States</cop><pub>by the American College of Cardiology Foundation and the American Heart Association, Inc</pub><pmid>31524498</pmid><doi>10.1161/CIRCULATIONAHA.119.042929</doi><tpages>14</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0009-7322
ispartof Circulation (New York, N.Y.), 2019-10, Vol.140 (18), p.1463-1476
issn 0009-7322
1524-4539
language eng
recordid cdi_proquest_miscellaneous_2290967110
source EZB Electronic Journals Library
subjects Aged
Benzhydryl Compounds - pharmacology
Biomarkers - analysis
Diabetes Mellitus, Type 2 - complications
Diabetes Mellitus, Type 2 - drug therapy
Female
Glucosides - pharmacology
Heart Failure - drug therapy
Heart Failure - physiopathology
Humans
Male
Middle Aged
Stroke Volume - drug effects
Ventricular Dysfunction, Left - drug therapy
Ventricular Function, Left - drug effects
title Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T15%3A24%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Dapagliflozin%20Effects%20on%20Biomarkers,%20Symptoms,%20and%20Functional%20Status%20in%20Patients%20With%20Heart%20Failure%20With%20Reduced%20Ejection%20Fraction:%20The%20DEFINE-HF%20Trial&rft.jtitle=Circulation%20(New%20York,%20N.Y.)&rft.au=Nassif,%20Michael%20E&rft.aucorp=On%20behalf%20of%20the%20DEFINE-HF%20Investigators&rft.date=2019-10-29&rft.volume=140&rft.issue=18&rft.spage=1463&rft.epage=1476&rft.pages=1463-1476&rft.issn=0009-7322&rft.eissn=1524-4539&rft_id=info:doi/10.1161/CIRCULATIONAHA.119.042929&rft_dat=%3Cproquest_cross%3E2290967110%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c2925-9d7a4a5b3ad4bd098b92daa7810087f664e3c9c0ea0ab5ce542ae2fb6009f3a73%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2290967110&rft_id=info:pmid/31524498&rfr_iscdi=true